AVIEW LCS vs ASSURE Wearable ECG

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Coreline Soft
VS
by Kestra Medical Technologies

AI Verdict

Tool A is an AI-powered solution for diagnostic imaging analysis, focusing on lung cancer screening, COPD, and coronary artery calcification from CT scans. In contrast, Tool B is a wearable ECG device designed for continuous heart rate monitoring and data collection for at-risk cardiac patients. While both leverage AI in cardiology, their distinct approaches—CT image analysis versus real-time physiological monitoring—make them suitable for different clinical applications.

Choose AVIEW LCS if…

Choose AVIEW LCS if your primary need is an AI-driven solution for comprehensive cardiopulmonary assessment from low-dose CT scans, particularly for lung cancer screening and early detection of related conditions. This tool excels in automating the detection, analysis, and reporting of lung nodules, emphysema, and coronary artery calcification, streamlining radiology workflows and enhancing diagnostic accuracy.

View AVIEW LCS →

Choose ASSURE Wearable ECG if…

Choose ASSURE Wearable ECG if you require a non-invasive, continuous heart rate monitoring solution for at-risk cardiac patients in a remote setting. This wearable device is ideal for long-term data collection, automatic episode storage, and providing clinicians with real-time alerts and physiologic trend data through a dedicated remote patient platform.

View ASSURE Wearable ECG →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature AVIEW LCS ASSURE Wearable ECG
Pricing Subscription or one-off payment Unknown
Deployment Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) The ASSURE system is intended for use by a patient during their normal daily activities primarily in the home or community setting, but also hospitals, medical clinics, healthcare facilities and transport.
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ASSURE Wearable ECG

Tool B, the ASSURE Wearable ECG, demonstrates superior usability by prioritizing patient comfort and ease of use through its SensorFit Garment and intuitive mobile application for continuous monitoring. While Tool A streamlines radiology workflows, Tool B's focus on patient-centric design for long-term adherence in a wearable device offers a broader impact on user experience for both patients and clinicians.

Clinical Value

AVIEW LCS

Tool A, AVIEW LCS, offers comprehensive clinical value by providing AI-powered detection and analysis of lung nodules, emphysema, and coronary artery calcification from a single low-dose CT scan. This '3-in-1' solution enhances diagnostic accuracy and supports early detection across multiple critical conditions with detailed quantitative analysis.

Pricing & Value

Tie

Both Tool A and Tool B require direct contact for specific pricing information, indicating a lack of public transparency regarding their cost structures. While some general pricing models like subscription or one-off payments are mentioned for both, without concrete figures or detailed models, a definitive comparison of their value propositions is not possible.

Enterprise Readiness

AVIEW LCS

Tool A, AVIEW LCS, exhibits stronger enterprise readiness due to its highly flexible deployment options, including cloud, hybrid, local dedicated hardware, and local virtualized solutions, accommodating diverse IT infrastructures. Its explicit integration with PACS/RIS and third-party platforms further ensures seamless incorporation into existing hospital workflows.

Innovation

ASSURE Wearable ECG

Tool B, ASSURE Wearable ECG, showcases significant innovation in wearable medical technology with its SensorFit Garment, featuring non-adhesive cushioned ECG sensors, and Adaptive Patient Intelligence for robust motion artifact filtering. These advancements directly address key challenges in achieving accurate and comfortable long-term cardiac monitoring in real-world settings.

Support & Docs

ASSURE Wearable ECG

Tool B, ASSURE Wearable ECG, provides more extensive and readily accessible support, including a 24/7 ASSURE Helpline for both patients and providers, along with comprehensive patient-facing documentation like handbooks and app user manuals. While Tool A offers customer service contacts, Tool B's detailed and continuous support structure is more robust.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature AVIEW LCS ASSURE Wearable ECG
Name AVIEW LCS ASSURE Wearable ECG
Company Coreline Soft Co. Kestra Medical Technologies
Tagline AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment Innovative, intuitive, and mobile diagnostic and therapeutic technologies for cardiac patients.
Primary Categories Cardiology AI, Oncology AI, Radiology & Imaging AI Cardiology AI, Wearables & Remote Monitoring (RPM)
Core Functionality AI-powered solution for detection and analysis of lung nodules, COPD, and coronary artery calcification from CT scans. Non-therapeutic wearable device for continuous heart rate monitoring and data collection for at-risk cardiac patients.

Videos

Demos, reviews, and walkthroughs featuring AVIEW LCS and ASSURE Wearable ECG.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

AVIEW LCS is an AI-powered solution for the detection and analysis of lung nodules, chronic obstructive pulmonary disease (COPD), and coronary artery calcification from low-dose CT scans, enhancing diagnostic accuracy and streamlining radiology workflows. In contrast, ASSURE Wearable ECG is a non-therapeutic device designed for continuous heart rate monitoring and data collection for at-risk cardiac patients.
AVIEW LCS processes data from low-dose CT scans for its analysis. ASSURE Wearable ECG collects continuous heart rate and rhythm data via a wearable ECG device and mobile application.
AVIEW LCS provides Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass) from CT scans. ASSURE Wearable ECG offers continuous heart rate monitoring, automatic episode storage, alert-based notifications, and physiologic trend data from a wearable ECG device, utilizing Quad Channel Processingu2122 and Adaptive Patient Intelligenceu2122 to filter motion artifacts.
AVIEW LCS provides automated lung nodule detection and analysis, Lung-RADS classification and reporting, nodule volume quantification and 3D segmentation, emphysema quantification (LAA index), CAC scoring, automated comparison of nodules in follow-up CT scans, and comprehensive, automated report generation. ASSURE Wearable ECG offers automatic episode storage, alert-based notifications, and physiologic trend data, which are available for clinician review via the Kestra CareStation remote patient data platform.
AVIEW LCS offers integration with PACS/RIS and third-party platforms. ASSURE Wearable ECG integrates with its Kestra CareStation remote patient data platform for clinician review, and the patient app transmits data securely.

Backers

Who funded each tool's parent company.

ASSURE Wearable ECG

AI Tool Finder
AI-powered search. Results may not be comprehensive.